These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 32270215

  • 1. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Min GJ, Cho BS, Park SS, Park S, Jeon YW, Yahng SA, Shin SH, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim HJ.
    Ann Hematol; 2020 May; 99(5):973-982. PubMed ID: 32270215
    [Abstract] [Full Text] [Related]

  • 2. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X, Zhang H, Chen L, Wang M, Xi J, Liu X, Xie M, Li D, Gulati ES, Gong S, Wang H.
    Trials; 2018 Sep 05; 19(1):476. PubMed ID: 30185214
    [Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
    Chen L, Zhu HM, Li Y, Liu QF, Hu Y, Zhou JF, Jin J, Hu JD, Liu T, Wu DP, Chen JP, Lai YR, Wang JX, Li J, Li JY, Du X, Wang X, Yang MZ, Yan JS, Ouyang GF, Liu L, Hou M, Huang XJ, Yan XJ, Xu D, Li WM, Li DJ, Lou YJ, Wu ZJ, Niu T, Wang Y, Li XY, You JH, Zhao HJ, Chen Y, Shen Y, Chen QS, Chen Y, Li J, Wang BS, Zhao WL, Mi JQ, Wang KK, Hu J, Chen Z, Chen SJ, Li JM.
    Proc Natl Acad Sci U S A; 2021 Feb 09; 118(6):. PubMed ID: 33495363
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Lou Y, Tong H, Yu W, Wei J, Xu W, Mao L, Jin J.
    Leuk Res; 2019 Aug 09; 83():106168. PubMed ID: 31202077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW, Su YZ, Tao HF.
    Curr Med Sci; 2021 Jun 09; 41(3):491-497. PubMed ID: 34169421
    [Abstract] [Full Text] [Related]

  • 11. Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.
    Langdon K, Cosentino S, Wawryk O.
    Cancer Rep (Hoboken); 2024 Mar 09; 7(3):e2035. PubMed ID: 38507294
    [Abstract] [Full Text] [Related]

  • 12. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
    Stahl M, Tallman MS.
    Leuk Lymphoma; 2019 Dec 09; 60(13):3107-3115. PubMed ID: 31842650
    [Abstract] [Full Text] [Related]

  • 13. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Breccia M, Foà R.
    Expert Rev Hematol; 2019 Feb 09; 12(2):81-87. PubMed ID: 30572725
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, Cao YX, Yi Y, Yang JJ, Peng HL, Zhong HY, Li RJ.
    Acta Haematol; 2009 Feb 09; 121(1):1-8. PubMed ID: 19246888
    [Abstract] [Full Text] [Related]

  • 17. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
    Gill HS, Yim R, Kumana CR, Tse E, Kwong YL.
    Cancer; 2020 Jul 15; 126(14):3244-3254. PubMed ID: 32365228
    [Abstract] [Full Text] [Related]

  • 18. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Yang S, Ma R, Yuan X, Jiang L, Shi J, Yang J, Lei P, Zang Y, Chen X, Zhang Y, Liu Z, Guo J, Zhang L, Zhu X, Zhu Z.
    Clin Lymphoma Myeloma Leuk; 2020 Jul 15; 20(7):e382-e391. PubMed ID: 32336675
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia.
    Wu Y, Ke P, Zhou H, Wu D, Chen S, Qiu H, Han Y, Li C, Ma X, Sun A, Tang X, Hu X.
    Hematology; 2021 Dec 15; 26(1):271-276. PubMed ID: 33631089
    [Abstract] [Full Text] [Related]

  • 20. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.
    Ann Hematol; 2018 Oct 15; 97(10):1797-1802. PubMed ID: 29951912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.